What Is The Survival Rate For Triple Negative Breast Cancer
Survival rates are a way to discuss the prognosis and outlook of a cancer diagnosis. The number most frequently mentioned is 5-year survival. Many patients live much longer, and some die earlier from causes other than breast cancer. With a constant change and improvement in therapies, these numbers also change. Current 5-year survival statistics are based on patients who were diagnosed at least 5 years ago and may have received different therapies than are available today.
Below are the statistics from the National Cancer Instituteâs SEER database for survival of all patients with breast cancer, by tumor stage:
How Do Treatment Options Differ Between Lumpectomies And Mastectomies
We know that if you get a lumpectomy, you do need radiation therapy. They go hand in hand, you need to radiate your entire breast. If we compare outcomes for someone who got a lumpectomy and radiation compared to a mastectomy, we know that the outcomes are the same, meaning the survival is going to be the same.
Generally speaking, if I have a patient who has a tumor that’s small enough for a lumpectomy, I do present them with a choice. Would you like to get a lumpectomy and radiation or choose a mastectomy? Again, we do have that choice left to the patient because again, from our standpoint, the outcomes to the patient will be the same.
The only case I will say that where this discussion also becomes a bit more complex is if someone has an underlying genetic mutation because then the issue isn’t just if I have my lumpectomy and radiation will this cancer come back, it’s also, could I get a new breast cancer in the breast tissue that’s left behind because I have a genetic predisposition and my chances of getting a new cancer are higher than the average patient. Should I get a mastectomy instead of a lumpectomy? Because I know that having a breast, in general, puts me at a higher risk for getting a new cancer.
How Common Is Triple Negative Breast Cancer
15% of all breast cancers over 8,000 cases a year in the UK are triple negative.
Triple negative breast cancer is more common in:
- women who have inherited an altered BRCA gene
- black women
- women who have not yet reached the menopause
- women under 40
Some types of breast cancer are more likely to be triple negative than others. These include medullary and metaplastic breast cancer. However, most people with triple negative breast cancer have invasive ductal breast cancer as this is the most common type of breast cancer in general.
Also Check: Invasive Breast Cancer Definition
Trials For Advanced Triple Negative Breast Cancer
Trials are comparing different types of chemotherapy to see which are better at treating advanced disease. For example, researchers are waiting for the results of the Triple Negative Trial to find out whether it is better to use carboplatin or docetaxel.
Research is looking at using targeted cancer drugs alongside other treatments. For example, a trial is using a drug called atezolizumab in combination with chemotherapy. Some trials are testing a drug called pembrolizumab. Researchers think that these targeted drugs on their own might help to control the growth of the cancer.
The Microenvironment A Novel Source Of Information And Noise For Subtype Discovery
TNBC tumors have also been stratified according to their immunogenomic profile. The analysis of 29 immune-associated gene sets defined three clusters in four BC datasets. The subsets were called immunity low, immunity medium, and immunity high. The latter group was characterized by greater immune cell infiltration and anti-tumor immune activities associated with a better prognosis . The tumor microenvironment is also known to impact TNBC outcome, defining response subtypes. TNBC presents the highest proportion of TILs in comparison with other BC subtypes . Its presence is associated with a better prognosis , higher rates of complete pathological response to neoadjuvant chemotherapy, and better response to immunotherapy . In another study, a high number of TILs was associated with enhanced survival. In contrast, increased levels of the immunosuppressor markers, such as PD-L1, CD163, and FOXP3, or a glycolytic microenvironment, determined by MCT4 expression, predicted a worse outcome. Together, these parameters were used to subset 174 TNBC tumors into four clusters. Clusters 1 and 2 defined by high TILs and low PD-L1 and FOXP3 showed better survival than clusters 3 and 4, both associated with increased PD-L1, FOXP3, and stromal MCT4 .
Also Check: Breast Cancer Spread To Brain Life Expectancy
Clinical Characteristics Epidemiology And Risk Factors
Triple-negative breast tumors have been characterized by several aggressive clinicopathologic features including onset at a younger age, higher mean tumor size, higher-grade tumors, and, in some cases, a higher rate of node positivity. A histologic study of basal-like tumors, of which all were ER/HER2negative, illustrated marked increases in mitotic count, geographic necrosis, pushing borders of invasion, and stromal lymphocytic response. The majority of triple-negative breast carcinomas are ductal in origin however, several other aggressive phenotypes appear to be overrepresented, including meta-plastic, atypical or typical medullary, and adenoid cystic.
In parallel with our understanding of the molecular basis of triple-negative breast cancer, our awareness of the epidemiology and risk factors associated with this disease process has matured, specifically related to age and race. Among approximately 500 women evaluated in the Carolina Breast Cancer Study, those with basal-like tumors were more likely to be African-American and premenopausal . These investigators observed a particularly high prevalence of basal-like tumors among premenopausal, African-American women compared to postmenopausal African-American women and nonAfrican-American women of any age . These findings are consistent with several large-scale, population-based studies indicating that triple-negative breast cancers are more likely to occur among premenopausal women of African-American descent.
What Is The Risk For Triple
The disease can affect anyone, but is more likely to show up in those who are:
- Younger than age 50 .
- Black or Latinx.
- Living with a genetic condition called BRCA mutation that increases the risk for breast cancer and other forms of cancer. Most cancers diagnosed in people with the BRCA1 mutation are triple negative.
Don’t Miss: Tubular Cancer Of The Breast
Risk Factors For Triple
Doctors arent sure what makes you more likely to get triple-negative breast cancer. Not many women do it only affects up to 20% of those who have breast cancer. Youre most at risk for triple-negative breast cancer if you:
- Are African-American or Latina
Also Check: What Percentage Of Breast Cancer Is Hereditary
Triple Negative Breast Cancer Survival Statistics
Triple Negative Breast Cancer or TNBC is a diagnosis of a type of breast cancer that does not have one of the three most common identifiers. It means that it is negative for the three most common receptors that are typically identified during the testing process to determine which type of treatment is best to fight the cancer. A diagnosis of TNBC means that HER 2 gene is not present, estrogen and progesterone receptors are also not present in the tumor. While it sounds quite awful because of the triple negative factor and it can be a little different to treat it can actually be more responsive in the early stages to chemotherapy than other types of cancers.
Don’t Miss: Stage Iii Breast Cancer Prognosis
When Should I Go To The Emergency Room
You might also have unusually strong side effects from your cancer treatment. While your healthcare provider likely gave you medication to help control your side effects, you should go to the emergency room if your side effects continue despite medication.
Many cancer treatments affect your immune system, increasing the chance you will develop infections. Symptoms that might require an emergency room visit during treatment are:
- Fever of 100.5 and above.
- Persistent nausea and vomiting.
Oncogene Expression May Negatively Impact Breast Cancer Results
A comparatively new addition to the discussion of prognosis and breast cancer survival data is oncogene expression. An oncogene is a small fragment of genetic material which can causeÃ¢ ordinary cells to eventually become malignant, and which can be carried on a chromosome. The oncogene HER-2 in particular is linked to aggressive breast cancers. On average, women with HER-2 amplification get a substantially greater danger of dying within a couple of years from breast cancer, in comparison to girls without HER-2 amplification.
Thats some reviews about How Fast does triple negative cancer grow. From the above article you dont need to completely trust. Because if we keep a healthy life pattern so cancer can get away from ourselves. For information about other cancer diseases you can look it up on this website.
Is Keytruda Right For You
Keytruda is FDA-approved to treat certain types of triple-negative breast cancer.
Triple-negative breast cancer is breast cancer that is:
Triple-negative breast cancers are usually more aggressive, harder to treat, and more likely to come back than cancers that are hormone-receptor-positive or HER2-positive. Triple-negative breast cancers don’t usually respond to hormonal therapy medicines or the medicines that target the HER2 protein.
Keytruda may be an option for people with triple-negative breast cancer that is:
- unresectable locally advanced breast cancer
- metastatic breast cancer
- early-stage breast cancer with a high risk of recurrence
Unresectable locally advanced breast cancer is breast cancer that has spread outside the breast to other tissues in the breast area. Unresectable means that it cant be removed with surgery.
Metastatic breast cancer is cancer that has spread to other parts of the body away from the breast, such as the bones or liver.
Keytruda also may be an option for people diagnosed with:
Inoperable Breast Cancer Is Often Still Treatable
Stage 3C breast cancer is divided into operable and inoperable stage 3C breast cancer. However, the term inoperable is not the same as untreatable.
If your physician uses the word inoperable, it may simply mean that a simple surgery at this time would not be enough to get rid of all the breast cancer that is within the breast and the tissue around the breast. There must be healthy tissue at all of the margins of the breast when it is removed. Keep in mind that the breast tissue goes beyond the breast mound it goes up to the clavicle and down to a few inches below the breast mound. There must also be tissue to close the chest wound after the surgery is performed.
Another treatment method may be used first to shrink the breast cancer as much as possible before surgery is considered.
Also Check: Treatment For Malignant Neoplasm Of Breast
Read Also: Breast Cancer Weight Gain Symptom
What Do These Studies Mean For Me As A Triple Negative Breast Cancer Patient
The University of Wisconsin researchers state in the publication of the research that our findings provide proof-of-principle preclinical evidence to support a clinical trial combining dietary methionine restriction and . As of the writing of this post 3 trials are currently recruiting subjects.
I will be monitoring for the published version of these studies and will share the information with you. These results are very promising especially for the triple negative breast cancer community that is currently without a targeted therapy. To stay up to date on the latest information and research that will help you to use nutrition to compliment your cancer treatment, sign-up to join my email list. One of many benefits is that you receive in-depth information and updates on new findings in the cancer research world.
Definitions And Molecular Features
It is important to clarify the relationship between triple-negative breast cancer and the basal-like phenotype. Triple-negative is a term based on clinical assays for ER, PR, and HER2, whereas basal-like is a molecular phenotype initially defined using cDNA microarrays. Although most triple-negative breast tumors do cluster within the basal-like subgroup, these terms are not synonymous there is up to 30% discordance between the two groups. In this review we will use the term basal-like when microarray or more comprehensive immunohistochemical profiling methodology was used, and triple-negative when the salient studies relied on clinical assays for definition.
Also Check: Suspicious Malignancy Breast
What Questions Should I Ask My Doctor
You will have lots of questions about your cancer, starting with your diagnosis. Here are some basic questions you might ask:
- What is triple negative breast cancer?
- How do you know my cancer is triple negative breast cancer?
- Why did I get this cancer?
- Do I need genetic testing?
- Has my breast cancer spread, and if so, how far has it spread?
- What is the stage of my cancer?
- What is my prognosis or expected outcome?
- What treatments do you recommend?
- Why do you recommend those treatments?
- What are those treatment side effects?
- Will I need surgery? If so, what surgery do you recommend and why?
- Im interested in participating in clinical trials. Are you able to help me find one?
- Do you know if there are any local support groups?
A note from Cleveland Clinic
Triple negative breast cancer is one of the more challenging breast cancers to treat. You might be discouraged by what you have read about triple negative breast cancer. But there are a number of very effective treatments for triple negative breast cancer, including immunotherapy, chemotherapy, surgery and radiation. And every day researchers learn more about this rare cancer. Their knowledge is your power. If youre concerned you arent getting the straight story about your cancer, ask your healthcare provider to walk you through your diagnosis and treatment options.
Symptoms Of Triple Negative Breast Cancer
The symptoms of triple negative breast cancer are similar to other breast cancer types.
Symptoms can include:
- a new lump or thickening in your breast or armpit
- a change in size, shape or feel of your breast
- skin changes in the breast such as puckering, dimpling, a rash or redness of the skin
- fluid leaking from the nipple in a woman who isnt pregnant or breast feeding
- changes in the position of nipple
Make an appointment to see your GP if you notice anything different or unusual about the look and feel of your breasts.
Also Check: What Is Stage 3 Breast Cancer
Can Tnbc Be Prevented
Researchers dont know all the factors that cause triple negative breast cancer. They have identified the BRAC1 gene mutation as one potential cause for triple negative breast cancer. Unfortunately, you cant prevent BRAC1 because you inherit this gene mutation from your parents.
But there are steps that help prevent breast cancers, including TNBC:
- Maintain a healthy weight.
- Exercise on a regular basis.
- Know your family medical history.
- Monitor your breast health. Studies show 95% of women whose breast cancer was treated before it could spread were alive four years after diagnosis.
- Talk to your healthcare provider about genetic testing for the BRCA gene if you have a family history of breast cancer, ovarian cancer, pancreatic or prostate cancer. If you have the BRCA gene, there are steps you can take to prevent breast cancer.
How Serious Is Triple
Compared to other subtypes of breast cancer, triple-negative breast cancer has a worse prognosis. This means it is more likely to grow quickly and come back in the first few years after treatment.
Read Also: Nipple Piercing And Breast Cancer
Breast Cancers Survival Is Influenced By Tumor Grade
Grade identifies the size and shape of the malignant breast cancer cells. At the event the breast cancer cells look very different than normal breast tissue cells, and random in appearance, they can be called, that was badly differentiated and described as âhigh gradeâ. Higher level breast cancer cells tend to really have a poorer prognosis.
Recommended Reading: How Likely Am I To Get Breast Cancer
Vaccine Designed To Prevent Triple
Disclosures: We were unable to process your request. Please try again later. If you continue to have this issue please contact .
Researchers at Cleveland Clinic have initiated a first-of-its-kind study of a vaccine designed to ultimately prevent triple-negative breast cancer the deadliest form of the disease.
The phase 1 study will determine the maximum tolerated dose of the vaccine in patients with early stage, triple-negative breast cancer and evaluate immune response to the vaccine. The FDA recently approved the vaccine as an investigational new drug, enabling Cleveland Clinic and partner Anixa Biosciences Inc. to undertake the study.
G.Thomas Budd, MD, Vincent K. Tuohy, PhD,: Cleveland Clinic.
Were in the very first stages, and we need to study the side effects and ensure that the vaccine produces an appropriate immunologic response at a dose that we can safely give,G.Thomas Budd, MD, of Cleveland Clinics Taussig Cancer Institute and principal investigator of the study, said in an interview with Healio. But in the long term, we are optimistic that it will be useful in the preventive setting.
Budd discussed the retired protein hypothesis behind the vaccines development and its potential value against breast cancer.
Healio: How did this vaccine come about?
Healio: What led tothis hypothesis?
Healio: What will the trial entail?
Healio: What will be the next step?
Healio:For which patients would this vaccine ultimately be indicated?
For more information:
Don’t Miss: Stage 3b Breast Cancer
Stage 3 Breast Cancer Treatment Options
Treatment for stage 3 breast cancers typically involves a combination of surgery along with chemotherapy to shrink the tumor before surgery and radiation after surgery to treat the chest wall and/or lymph nodes. Lymph nodes will also likely be removed during surgery.
Read Also: De Novo Metastatic Breast Cancer Symptoms